The investigational menin inhibitor is being evaluated in a registrational phase 2 trial for patients with relapsed or refractory acute leukemia.
|Videos|January 15, 2014
Differences Between NCI, MSKCC, and UPenn CAR-Modified T Cells
Author(s)Renier J. Brentjens, MD, PhD
Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center, discusses the differences between the CAR-modified T cells of three institutions.
Advertisement
Clinical Pearls
Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center, discusses the differences between the CAR-modified T cells of three institutions.
- Only the National Cancer Institute, Memorial Sloan-Kettering Cancer Center (MSKCC), and the University of Pennsylvania (UPenn) have reported significant anti-tumor responses using CAR-modified T cells in B cell malignancies
- It is unknown whether the design of the receptor and the methodology in which the receptor is introduced into the T cell make a clinically meaningful difference
- MSKCC and UPenn are currently conducting a study to evaluate any potential differences in clinical activity
Advertisement
Related to this article
Experts weigh continuous BTK inhibitors vs fixed-duration CLL therapy, highlighting TP53/17p risk, patient logistics, and subtle zanubrutinib–acalabrutinib tolerability differences.
New study shows CT-measured body fat, not BMI, links obesity to higher lung cancer risk via immune T-cell changes—hinting at prevention through weight loss.
Elranatamab reduced the risk of disease progression or death vs standard care in patients with R/R myeloma after prior anti-CD38 therapy and lenalidomide.
The phase 2 I-SPY2.2 trial found promising responses with rilvegostomig plus trastuzumab deruxtecan in biomarker-defined, immune-positive tumors.
The FDA granted orphan drug designation to Cardiff Oncology’s PLK1 inhibitor onvansertib for relapsed or refractory CMML after early phase 1 activity.
The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with polycythemia vera receiving standard-of-care therapy.
At Rutgers Cancer Institute, neuro-oncologists met to discuss the latest trends in precision brain cancer care with FET-PET imaging, advanced molecular testing, and same-day multidisciplinary clinics.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
3
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
4
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
5